FGEN’s DMD drug targeting Fibrosis, page-3

First 3 Last

Share
Profile

Follow
itsagas

12,779 Posts.

1290

04/07/20

10:27

Post #: 45641059
Share

Originally posted by itsagas: ↑

“most on HC fail to realise that the sp works on Future EarningsRoche paid Sarepta $1 billion for a Gene therapy DMD drug that is in its infant stage...(future earnings)For Anp to get $5 we have to have. MC of $3 billion..Even if we only get 1% of the inflammation market worth $104 bill ...that will do the job.....$$Not all pie in the sky...”

George: Thank you for all your informative posts.
We must be on the same page re Future Earnings $$
People here have been laughing at my Predictions
$5 in 2 years...

George you put out a post regarding your Fund Managers thoughts on Anp and now your latest post re Fibrogen confirms my post above written a c
ouple of days ago...The correlation is uncanny because they both confirm what I’ve said all along....

Even if Anp only get 1% of the inflammation market ( $105 billion )that’s $1 billion for Anp per annum ongoing.
So when you get Fibrogen with earnings of $15 mill per annum and they have a MC of $3.9 Billion.($600 mill on the Bank)
Anp can put $200 mill in the Bank ...in 16 months time frame as our Liscence fees for all the other Indications roll in.....

But for Anp to move forward in a big way we need a New young Chairman ( thank you Mr Moses for your service) we also need another Director to be replaced.
The new Chairman should be American with big connections ( Anp has the potential to be as big as Sarepta)...
We cannot afford Anp to move at a snails pace...
Mr Diamond and Mr Moses have been well Rewarded with generous options.. granted in Dec 2019..
Anp Board ... think of moving Anp forward for the benefit of the Owners(Shareholders) Leave your egos at the door knowing you have helped build the Largest Biotech in Australia ....$$

Expand

Sam: Strongbridge got rid of Brian Paul... (did not perform )and replaced him with Richard.. Anp need a person like Richard to move Anp forward..

ANP Price at posting: 8.4¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 37 more messages in this thread...

First 3 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.7¢		Change 0.000(0.00%)		Mkt cap ! $69.41M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	100000	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	11000	1

View Market Depth

No.	Vol.	Price($)
1	100000	0.079
2	31331	0.078
1	48919	0.077
2	113467	0.075
1	200000	0.072

Price($)	Vol.	No.
0.080	11000	1
0.081	120000	1
0.083	206000	2
0.085	250000	2
0.087	25001	1

Last trade - 10.19am 06/05/2024 (20 minute delay)

PER (ASX) Chart

Day chart unavailable

FGEN’s DMD drug targeting Fibrosis, page-3

Featured News

Dancing to that same 70s tune, China, and why I'm backing gold

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Sold out signs go up for RIU Resources Roundup in Sydney

Car EV-olution accelerates Oz into pole position

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Buyers (Bids)

Sellers (Offers)

Featured News

FGEN’s DMD drug targeting Fibrosis, page-3

Featured News

Top Stories

Dancing to that same 70s tune, China, and why I'm backing gold

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Sold out signs go up for RIU Resources Roundup in Sydney

Car EV-olution accelerates Oz into pole position

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Buyers (Bids)

Sellers (Offers)

Featured News